PRMT8

Across TCGA pan-cancer cohorts, PRMT8 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PRMT8 data layer compared with 5 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRMT8 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated PRMT8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and ESCA show a favorable association.

LUAD, BLCA, and DLBC are the cancer types where PRMT8 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.739	0.595	<.001	101	view →
BLCA	OS	Tertile	IV	0.287	0.597	<.001	75	view →
DLBC	DFS	Median	IV	0.223	1.000	.001	54	view →
ESCA	OS	Quartile	II,III,IV	0.907	0.418	<.001	41	view →
UVM	DFS	Median	All	0.481	0.879	.003	36	view →
ACC	OS	Median	II,III,IV	0.746	0.920	.001	34	view →
SARC	OS	Tertile	All	0.640	0.801	.003	23	view →
THCA	OS	Tertile	All	1.000	0.850	.018	20	view →
SKCM	DFS	Tertile	All	0.719	0.506	.014	19	view →
COAD	OS	Tertile	All	0.699	0.872	.003	17	view →
UCEC	DFS	Median	III,IV	0.474	0.654	.022	14	view →
THYM	OS	Median	All	0.965	0.745	.006	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PRMT8–LUAD (DFS)

Open the LUAD breakdown →